Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01702155 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of DFP-10917 in Patients With Acute Leukemia
A Phase 1 study, sponsored by Delta-Fly Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT01702155: Completed Phase 1 study, sponsored by Delta-Fly Pharma.
NCT01702155 is a Phase 1 study that has completed, run by Delta-Fly Pharma. The registered enrollment target is 69 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01702155, a Phase 1 study, has completed, sponsored by Delta-Fly Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of DFP-10917 given via continuous 7 or 14 day infusion to patients with acute leukemias (AML or ALL).
Interventions
- DRUG DFP-10917
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2012-10-10 |
| Est. Completion | 2017-10-11 |
| Phase | Phase 1 |
What the finished NCT01702155 record still lists
NCT01702155 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% higher).
The record links to 0 conditions, and to 1 intervention - of which DFP-10917 is the first listed.
NCT01702155 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01702155 about?
NCT01702155 is a clinical study titled "Phase I/II Study of DFP-10917 in Patients With Acute Leukemia". The purpose of this study is to determine the safety and efficacy of DFP-10917 given via continuous 7 or 14 day infusion to patients with acute leukemias (AML or ALL).
What is the current status of trial NCT01702155?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2012-10-10. Estimated completion is 2017-10-11.
What interventions are being tested in trial NCT01702155?
The interventions under investigation include: DFP-10917 (DRUG).
Who is sponsoring clinical trial NCT01702155?
This trial is sponsored by Delta-Fly Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01702155's enrollment target sits among peer trials
69 774th of 2000 higher than 1,225 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI